Characterization of novel CSF Tau and ptau biomarkers for Alzheimer's disease. - Test2 - elhamkhani - TriplyDB

Characterization of novel CSF Tau and ptau biomarkers for Alzheimer's disease.

Characterization of novel CSF Tau and ptau biomarkers for Alzheimer's disease.

http://www.wikidata.org/entity/Q35014708

about

Expanding the Repertoire of Biomarkers for Alzheimer's Disease: Targeted and Non-targeted Approaches The potential of pathological protein fragmentation in blood-based biomarker development for dementia - with emphasis on Alzheimer's disease Passive immunization with phospho-tau antibodies reduces tau pathology and functional deficits in two distinct mouse tauopathy models Intrinsic Tau Acetylation Is Coupled to Auto-Proteolytic Tau Fragmentation Immunological memory to hyperphosphorylated tau in asymptomatic individuals.Cerebrospinal fluid biomarkers in parkinsonian conditions: an update and future directions Divergent CSF τ alterations in two common tauopathies: Alzheimer's disease and progressive supranuclear palsy Tau monoclonal antibody generation based on humanized yeast models: impact on Tau oligomerization and diagnostics Tau passive immunization inhibits not only tau but also Aβ pathology Review: Tau in biofluids - relation to pathology, imaging and clinical features.Levels of tau protein in plasma are associated with neurodegeneration and cognitive function in a population-based elderly cohort.Cerebrospinal fluid tau and amyloid-β1-42 in patients with dementia.Extracellular truncated tau causes early presynaptic dysfunction associated with Alzheimer's disease and other tauopathies Scalable Production of iPSC-Derived Human Neurons to Identify Tau-Lowering Compounds by High-Content Screening.Mass-Spectrometry-Based Method To Quantify in Parallel Tau and Amyloid β 1-42 in CSF for the Diagnosis of Alzheimer's Disease.Tau Antibody Targeting Pathological Species Blocks Neuronal Uptake and Interneuron Propagation of Tau in Vitro.Comprehensive Quantitative Profiling of Tau and Phosphorylated Tau Peptides in Cerebrospinal Fluid by Mass Spectrometry Provides New Biomarker Candidates.Tau passive immunization blocks seeding and spread of Alzheimer hyperphosphorylated Tau-induced pathology in 3 × Tg-AD mice.Probing Conformational Dynamics of Tau Protein by Hydrogen/Deuterium Exchange Mass Spectrometry.Tau Diagnostics and Clinical Studies.Proteomic studies of cerebrospinal fluid biomarkers of Alzheimer's disease: an update.Non-Phosphorylated Tau as a Potential Biomarker of Alzheimer's Disease: Analytical and Diagnostic Characterization.Tau pathology in Creutzfeldt-Jakob disease revisited.A liquid chromatography tandem mass spectroscopy approach for quantification of protein methylation stoichiometry.Detection of Aggregation-Competent Tau in Neuron-Derived Extracellular Vesicles.Two novel blood-based biomarker candidates measuring degradation of tau are associated with dementia: A prospective study.Tau Proteolysis in the Pathogenesis of Tauopathies: Neurotoxic Fragments and Novel Biomarkers.The Past and the Future of Alzheimer's Disease Fluid Biomarkers.Understanding biomarkers of neurodegeneration: Ultrasensitive detection techniques pave the way for mechanistic understanding.Tau Kinetics in Neurons and the Human Central Nervous System Ultra-sensitive detection of protein biomarkers for diagnosis of Alzheimer's disease Epitope determines efficacy of therapeutic anti-Tau antibodies in a functional assay with human Alzheimer Tau

P2860

Q26770708-B5DB4D6C-770D-4133-BC75-6A06A3733E88 Q26853347-B50F8191-0A61-4C57-A89B-E83E0EB635FD Q27308146-EB8B3802-2C4C-4DFB-BFDF-2D8ACD1D3A00 Q28552366-46C689AD-F479-4D48-8FCB-7D990750BCD4 Q33559360-0E4F4615-BD0B-44EE-AB7E-EF49C9D71F61 Q34237637-E106EE23-B97B-4E64-A04D-10C28AF63836 Q34633220-687067DC-A585-4AB8-B9D7-53B48C294E09 Q35080258-55FC0104-C0B9-46C7-BF9A-312DBFF7C514 Q37579019-E1A8988E-94EB-46B4-AF79-494A568CA626 Q39068040-78FC16B7-9D5E-4ABB-B845-623582D5A7E7 Q40642279-C05126A9-8D79-4971-A46E-DFA4224B4760 Q40777128-2E40EC87-3C4A-40CE-A812-D13F9DC6E3D2 Q42371467-017AB9E4-9A81-4DE5-9A02-98455812451F Q42376445-85954C87-49C6-4B48-8812-5EE0B99D3F59 Q46161119-3895C804-0A85-4B21-B2CD-4E2B52BAB397 Q46383545-7D6681E2-5801-4943-9503-6C06E76C138F Q46488626-D6F851E1-CBDA-44BB-A817-D728C2401C69 Q47547728-78781EC8-3ED9-4842-80BD-D74B92DEA8E0 Q47710937-515F052F-D886-48C2-9963-013659679102 Q47870437-5123EF54-CC1C-4B73-B26F-33328C71B89B Q47932570-B56A74E7-E5CF-4560-87CE-DE2FBA89D1C6 Q48497489-E4C68B5E-41DC-48F9-BD96-3E70D8552643 Q48640345-DA7A7A06-287F-44E1-B8EB-AF326C622EA3 Q50178775-EA46C930-CAD4-4368-BA7E-9A990D34F43A Q51766334-060D1972-978B-483B-874A-635067A23BDB Q52594155-0CFDD222-5055-487F-92FE-4C10C76B2145 Q52598834-A674181A-E4ED-41A6-9EA8-4CB609516459 Q52644601-3FBCAAF0-F9BB-439A-9D47-E715F7CBEA4B Q53362342-B1EF3D1B-DFE8-4ECA-95EC-B49438C3A84B Q57215461-7A9D487A-57C2-435B-B2C3-C96C136C7C4B Q58376432-929F34A5-AAB3-4519-BABD-91EE144B326C Q58708935-CAD36B7B-512A-4F66-91FD-8C9F45E51079

P2860

Characterization of novel CSF Tau and ptau biomarkers for Alzheimer's disease.

http://www.wikidata.org/entity/Q35014708

description

2013 nî lūn-bûn

@nan

2013 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

name

Characterization of novel CSF Tau and ptau biomarkers for Alzheimer's disease.

@ast

Characterization of novel CSF Tau and ptau biomarkers for Alzheimer's disease.

@en

type

label

Characterization of novel CSF Tau and ptau biomarkers for Alzheimer's disease.

@ast

Characterization of novel CSF Tau and ptau biomarkers for Alzheimer's disease.

@en

prefLabel

Characterization of novel CSF Tau and ptau biomarkers for Alzheimer's disease.

@ast

Characterization of novel CSF Tau and ptau biomarkers for Alzheimer's disease.

@en

P1433

Q35014708-8057E425-998A-424C-85A1-B41DBB79E557

P1476

Q35014708-1B1272F5-3970-4278-838A-CD5BB10DCF59

P2093

Q35014708-278231F1-ACD8-4D3A-AD47-0C39F70F4A77

Q35014708-3D828F3E-9A9E-438F-B699-7E06B9331098

Q35014708-61A056BD-D3A0-4879-BBB1-75711A0A4D86

Q35014708-6913FDAE-58F2-488D-9366-14F7D68AEAFE

Q35014708-7177DBC3-8C85-4C72-9F1A-DB3308BC5411

Q35014708-A2740F20-F074-4D89-BC59-25A9AD44E588

Q35014708-B710F2DF-558E-4C8E-841B-923D60E95712

Q35014708-B8FBDBD8-356B-43EC-8198-F27B27FB7BBA

Q35014708-DF1FD5EB-B90E-4803-9036-D6E7887C6B85

Q35014708-F67BB294-0B8B-47F1-889F-B84A3EF36947

P2860

Q35014708-060A1827-5E9B-4ACE-BF8D-46539402390F

Q35014708-06124CAA-02BF-450E-BB5B-1428EE54DA9F

Q35014708-0670DD61-2B20-4263-9BDF-9ACEFB169606

Q35014708-07A0C9CA-BCAE-4BF8-99C3-EA8B6964CBB2

Q35014708-07ABD9FC-9834-448F-ACBC-208C3F94F182

Q35014708-09FCF98F-0746-42BC-85E3-D0178B4CDB3C

Q35014708-141BA7EA-089E-4BC7-B419-D5D4B7150F10

Q35014708-154D6B92-27D4-4FA3-82A8-8D18001E3CDD

Q35014708-15ED180C-1FC9-4826-8871-784D9E2F853A

Q35014708-173349F6-359E-4BAF-B066-C986E8D91125

P304

Q35014708-D5DBBCFE-5AA3-4C2B-B2E7-D43B6F441855

P31

Q35014708-793A59D6-8F83-4595-A0FB-648C9B5C4CEA

P356

Q35014708-46FA1E52-01DF-4BCF-A827-80C64219485C

P407

Q35014708-4F69D969-AF2A-4D73-9D58-13A681250CDB

P433

Q35014708-23C9F98A-D54C-4C6C-898A-03514D65BF2E

P478

Q35014708-BA79E6FB-1EEC-46A1-96F7-A43EACC551FC

P50

Q35014708-0258CA8B-2B48-4E43-9E05-6C5BEFD974E6

Q35014708-59633911-89D7-49DB-A66C-851623789D37

Q35014708-A0B1751E-3626-4A13-AAB4-BFF914EE4491

P577

Q35014708-0DD7D0B7-F53C-4993-B431-75DAFDEF3F13

P5875

Q35014708-1FDE9B42-9C6A-4005-95BC-F11A5D75E016

P698

Q35014708-5F49D5D2-687F-40C0-A505-A922E30A340E

P921

Q35014708-1A5053D3-A7D2-4211-916C-DF9C9BFDC2E8

Q35014708-8419093D-13CB-478A-A80F-60FB59149BFF

P932

Q35014708-1EE1CBF3-4FE8-4CCC-AD91-0E784C1E6836

P356

JOURNAL.PONE.0076523

P1433

P1476

Characterization of novel CSF Tau and ptau biomarkers for Alzheimer's disease.

@en

P2093

Anthony J Lanzetti

http://www.w3.org/2001/XMLSchema#string

Charles F Albright

http://www.w3.org/2001/XMLSchema#string

Flora Berisha

http://www.w3.org/2001/XMLSchema#string

Holly Soares

http://www.w3.org/2001/XMLSchema#string

J Randall Slemmon

http://www.w3.org/2001/XMLSchema#string

Jere E Meredith

http://www.w3.org/2001/XMLSchema#string

Michael Ahlijanian

http://www.w3.org/2001/XMLSchema#string

Robert J Neely

http://www.w3.org/2001/XMLSchema#string

Sethu Sankaranarayanan

http://www.w3.org/2001/XMLSchema#string

Valerie Guss

http://www.w3.org/2001/XMLSchema#string

P2860

Alzheimer's disease

Clinical and biomarker changes in dominantly inherited Alzheimer's disease.

Cerebrospinal fluid tau and ptau(181) increase with cortical amyloid deposition in cognitively normal individuals: implications for future clinical trials of Alzheimer's disease

Hyperphosphorylation and cleavage at D421 enhance tau secretion

Measurement of phosphorylated tau epitopes in the differential diagnosis of Alzheimer disease: a comparative cerebrospinal fluid study.

Age and diagnostic performance of Alzheimer disease CSF biomarkers.

Exosome-associated tau is secreted in tauopathy models and is selectively phosphorylated in cerebrospinal fluid in early Alzheimer disease.

Levels of nonphosphorylated and phosphorylated tau in cerebrospinal fluid of Alzheimer's disease patients : an ultrasensitive bienzyme-substrate-recycle enzyme-linked immunosorbent assay.

Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects.

Proteolytic processing of tau.

P304

e76523

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1371/JOURNAL.PONE.0076523

http://www.w3.org/2001/XMLSchema#string

P407

P433

10

http://www.w3.org/2001/XMLSchema#string

P478

8

http://www.w3.org/2001/XMLSchema#string

P50

Henrik Zetterberg

P577

2013-10-07T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

257650025

http://www.w3.org/2001/XMLSchema#string

P698

24116116

http://www.w3.org/2001/XMLSchema#string

P921

Alzheimer's disease

P932

3792042

http://www.w3.org/2001/XMLSchema#string